Virios Therapeutics (VIRI) Competitors $5.06 +0.11 (+2.26%) As of 08/25/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesInsider TradesOptions ChainSEC FilingsTrendsBuy This Stock VIRI vs. NBTX, OLMA, FULC, ABEO, CAPR, ZYBT, ADCT, BNTC, FDMT, and INBXShould you be buying Virios Therapeutics stock or one of its competitors? The main competitors of Virios Therapeutics include Nanobiotix (NBTX), Olema Pharmaceuticals (OLMA), Fulcrum Therapeutics (FULC), Abeona Therapeutics (ABEO), Capricor Therapeutics (CAPR), Zhengye Biotechnology (ZYBT), ADC Therapeutics (ADCT), Benitec Biopharma (BNTC), 4D Molecular Therapeutics (FDMT), and Inhibrx Biosciences (INBX). These companies are all part of the "pharmaceutical products" industry. Virios Therapeutics vs. Its Competitors Nanobiotix Olema Pharmaceuticals Fulcrum Therapeutics Abeona Therapeutics Capricor Therapeutics Zhengye Biotechnology ADC Therapeutics Benitec Biopharma 4D Molecular Therapeutics Inhibrx Biosciences Virios Therapeutics (NASDAQ:VIRI) and Nanobiotix (NASDAQ:NBTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation. Do institutionals and insiders hold more shares of VIRI or NBTX? 9.1% of Virios Therapeutics shares are held by institutional investors. Comparatively, 38.8% of Nanobiotix shares are held by institutional investors. 12.2% of Virios Therapeutics shares are held by insiders. Comparatively, 3.5% of Nanobiotix shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is VIRI or NBTX more profitable? Nanobiotix's return on equity of 0.00% beat Virios Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Virios TherapeuticsN/A -130.33% -115.00% Nanobiotix N/A N/A N/A Do analysts recommend VIRI or NBTX? Virios Therapeutics currently has a consensus target price of $5.00, suggesting a potential downside of 1.19%. Nanobiotix has a consensus target price of $8.00, suggesting a potential downside of 4.53%. Given Virios Therapeutics' higher probable upside, research analysts clearly believe Virios Therapeutics is more favorable than Nanobiotix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Nanobiotix 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media refer more to VIRI or NBTX? In the previous week, Nanobiotix had 2 more articles in the media than Virios Therapeutics. MarketBeat recorded 2 mentions for Nanobiotix and 0 mentions for Virios Therapeutics. Nanobiotix's average media sentiment score of 1.31 beat Virios Therapeutics' score of 0.00 indicating that Nanobiotix is being referred to more favorably in the news media. Company Overall Sentiment Virios Therapeutics Neutral Nanobiotix Positive Which has more risk and volatility, VIRI or NBTX? Virios Therapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Comparatively, Nanobiotix has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Which has stronger valuation & earnings, VIRI or NBTX? Virios Therapeutics has higher revenue and earnings than Nanobiotix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirios TherapeuticsN/AN/A-$5.30M-$0.27-18.74Nanobiotix-$11.61M-34.61-$73.73MN/AN/A SummaryNanobiotix beats Virios Therapeutics on 7 of the 12 factors compared between the two stocks. Get Virios Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VIRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIRI vs. The Competition Export to ExcelMetricVirios TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$97.45M$853.50M$5.74B$9.77BDividend YieldN/A4.84%4.40%4.08%P/E Ratio-18.741.1530.4126.04Price / SalesN/A26.26428.97104.72Price / CashN/A19.5625.7828.79Price / Book25.306.779.706.08Net Income-$5.30M-$4.17M$3.27B$265.64M7 Day Performance-4.53%3.84%3.94%3.11%1 Month Performance6.08%2.35%3.81%0.39%1 Year Performance2,246.94%12.14%31.26%18.52% Virios Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIRIVirios TherapeuticsN/A$5.06+2.3%$5.00-1.2%+2,250.8%$97.45MN/A-18.745NBTXNanobiotix0.767 of 5 stars$8.80+11.3%$8.00-9.1%+86.6%$379.23M$39.18M0.00100Positive NewsGap DownOLMAOlema Pharmaceuticals1.9626 of 5 stars$5.76+4.5%$24.00+316.7%-53.2%$378.17MN/A-2.9170News CoverageFULCFulcrum Therapeutics1.0229 of 5 stars$6.64-2.6%$7.57+14.0%-30.1%$368.90M$80M-5.44100ABEOAbeona Therapeutics4.4093 of 5 stars$6.91-3.1%$19.50+182.2%+27.1%$364.75M$400K9.8790CAPRCapricor Therapeutics3.052 of 5 stars$7.70-3.3%$22.56+192.9%+44.7%$363.91M$13.39M-4.70101ZYBTZhengye BiotechnologyN/A$7.84+4.4%N/AN/A$354.22M$25.53M0.00278ADCTADC Therapeutics1.4014 of 5 stars$3.24+3.5%$7.75+139.2%+0.5%$352.12M$70.84M-2.06310High Trading VolumeBNTCBenitec Biopharma1.3695 of 5 stars$12.71-2.3%$26.00+104.6%+46.0%$341.51MN/A-8.4220Positive NewsFDMT4D Molecular Therapeutics1.7222 of 5 stars$7.27+0.1%$30.40+318.2%-54.9%$339.06M$40K-2.06120Gap DownINBXInhibrx Biosciences1.6426 of 5 stars$23.87+2.3%N/A+87.7%$337.95M$200K-2.26166News Coverage Related Companies and Tools Related Companies Nanobiotix Alternatives Olema Pharmaceuticals Alternatives Fulcrum Therapeutics Alternatives Abeona Therapeutics Alternatives Capricor Therapeutics Alternatives Zhengye Biotechnology Alternatives ADC Therapeutics Alternatives Benitec Biopharma Alternatives 4D Molecular Therapeutics Alternatives Inhibrx Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIRI) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virios Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virios Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access